




The relative strengths and weaknesses of Ayala Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ayala Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 162% points. The greatest weakness of Ayala Pharmaceuticals Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 390%, being 127% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	115,015
Cost of Goods Sold	0
Intangible Assets	3,355
Liabilities, Current	3,918
Liabilities, Non-Current	0
Other Assets	149
Other Compr. Net Income	0
Other Expenses	-1,560
Other Liabilities	89
Other Net Income	79
Other Revenues	0
Property and Equipment	1,087
Research and Development	24,221
Selling, General and Administrative Expense	24,450

Output Variable	Value in 1000 USD
Assets	119,606
Liabilities	4,007
Expenses	47,110
Revenues	0
Stockholders Equity	115,599
Net Income	-47,031
Comprehensive Net Income	-47,031
BaseVar	85,401
ECR before Limited Liability	332%
Economic Capital Ratio	390%